Severe Respiratory Illness Associated With Middle East Respiratory Syndrome Coronavirus {#s1}
=======================================================================================

(MMWR 62:480, 2013) Reports of cases outside the Middle East raise concerns about the importation of Middle East respiratory syndrome coronavirus (MERS-CoV) to other geographic areas. Nosocomial outbreaks with transmission to healthcare personnel highlight the importance of infection control procedures. Recent data suggest that mild respiratory illness might be part of the clinical spectrum of MERS-CoV infection, and presentations might not initially include respiratory symptoms. In addition, patients with comorbid conditions or immunosuppression might be at increased risk for infection, severe disease, or both. Importantly, the incubation period might be longer than previously estimated. Finally, lower respiratory tract specimens (eg, sputum, bronchoalveolar lavage, bronchial wash, or tracheal aspirate) should be collected in addition to nasopharyngeal samples to evaluate patients under investigation.

The median age of patients is 56 years (range, 2--94 years), with a male-female ratio of 2.6:1.0. All patients were aged ≥24 years, except for 2 children, 1 aged 2 years and 1 aged 14 years. All patients had respiratory symptoms during their illness, with most experiencing severe acute respiratory disease requiring hospitalization. Three were in persons with mild respiratory illnesses. Several patients had accompanying gastrointestinal symptoms, including abdominal pain and diarrhea, and many cases occurred among persons with chronic underlying medical conditions or immunosuppression.

Eight clusters (42 cases) have been reported by 6 countries (France, Italy, Jordan, Saudi Arabia, Tunisia, and the United Kingdom) among close contacts or in healthcare settings and provide clear evidence of human-to-human transmission of MERS-CoV. In 1 secondary case the incubation period was estimated to be 9--12 days, longer than the previously estimated 1--9 days. Thus far, no evidence of sustained community transmission beyond the clusters has been reported in any country.

In some instances, MERS-CoV was not detected with polymerase chain reaction (PCR) in nasopharyngeal swab samples, but it was detected with PCR in lower respiratory tract specimens from these same patients.

Persons who develop severe acute lower respiratory illness within 14 days after traveling from the Arabian Peninsula or neighboring countries should be evaluated according to current guidelines (available at <http://www.cdc.gov/coronavirus/mers/case-def.html>). Persons who develop severe acute lower respiratory illness and who are close contacts of a symptomatic traveler who developed fever and acute respiratory illness within 14 days of traveling from the Arabian Peninsula or neighboring countries may be considered for evaluation for MERS-CoV. In addition, the Centers for Disease Control and Prevention (CDC) recommends that clusters of severe acute respiratory illness be investigated; if no obvious cause is identified, local public health officials should be notified and testing for MERS-CoV conducted, if indicated.

Testing of specimens for MERS-CoV is currently is being conducted at the CDC. The CDC\'s novel coronavirus 2012 real-time reverse-transcription PCR assay to test for MERS-CoV in clinical respiratory, blood, and stool specimens will be deployed to Laboratory Response Network laboratories in all 50 states over the coming weeks.

***Editorial comment.*** Since the first case in April 2012, a total of 72 cases with 38 deaths (53%) have been reported as of 21 June 2013. All reported cases were directly or indirectly linked to Saudi Arabia, Qatar, Jordan, or the United Arab Emirates. Most cases were reported by Saudi Arabia. The United Kingdom, Italy, France, and Tunisia have reported cases in returning travelers and their close contacts. Ill patients from Qatar and the United Arab Emirates have been transferred to hospitals in the United Kingdom and Germany. There have been a few asymptomatic patients as well as mildly ill patients.

The recommended methods of collection of lower respiratory tract specimens are precisely the way that nosocomial outbreaks of severe acute respiratory syndrome occurred because of aerosolization of virus during the procedure. H7N9 has also shown the propensity to cause hospital outbreaks. Clearly, appropriate infection control measures are needed for the general care of these patients and especially with lower respiratory tract specimen collections.

New 4-Strain Influenza Vaccine From Sanofi Pasteur Now Licensed by the FDA for a Broad Age Range of Children and Adults {#s2}
=======================================================================================================================

(From the Sanofi Pasteur Web site, 10 June 2013) Sanofi Pasteur, the vaccines division of Sanofi, announced that the US Food and Drug Administration (FDA) has approved its 4-strain influenza vaccine, Fluzone Quadrivalent vaccine, the newest addition to the Fluzone family of influenza vaccines. It is licensed for use in children aged ≥6 months, adolescents, and adults.

The 2013 influenza season will be the first in which quadrivalent influenza vaccines will be available in the United States. Until this year, seasonal influenza vaccines included only 1 B strain. Fluzone Quadrivalent vaccine includes 2 A strains and 2 B strains to help protect against influenza disease. Epidemics of influenza B occur every 2--4 years in all age groups.

For the past 35 years, influenza vaccines have been trivalent to help protect against 3 strains of influenza virus: a type A(H1N1), a type A(H3N2) and 1 type B. However, since the 2001--2002 season, 2 distinct influenza B types (the Victoria and Yamagata lineages) have cocirculated with varying prevalence, making it difficult to predict the next season\'s dominant B lineage strain. In 6 of the past 12 seasons, the dominant circulating B strain was from the B lineage not selected for the vaccine. Even in years where the correct B lineage strain was selected for the vaccine, some influenza disease was caused by the B lineage omitted from the vaccine, probably reducing overall vaccine effectiveness against circulating influenza viruses.

***Editorial comment.*** In fact, 2 approved quadrivalent influenza vaccines are already available, Fluarix and Flumist. Fluarix is recommended for patients \>3 years of age, and Flumist (the live attenuated nasal vaccine) is approved for patients aged 2--49 years. It is unclear whether Sanofi will have a quadrivalent Fluzone high-antigen vaccine available for the 2013--2014 influenza season.

It makes good sense to use a quadrivalent vaccine rather than a trivalent one; in my opinion, the exception would be in elderly patients if no high-antigen quadrivalent vaccine is available. In the 2012--2013 influenza season, when the major cause of illness was H3N2, the H3N2 component of the regular-antigen influenza vaccine had only 9% effectiveness in patients aged ≥65 years. Until and unless a high-antigen vaccine is demonstrated not to have any advantages over regular-antigen vaccines in elderly patients (and the data are not yet available), I would chose a trivalent high-antigen vaccine over a quadrivalent regular-antigen vaccine in these patients.

Update on Avian Influenza A(H7N9) Outbreak {#s3}
==========================================

(Prepared by section editor) As of 22 June 2013, only 1 case of avian influenza H7N9 has been reported since early May 2013 (onset on 21 May). This translates to 1 case in 6 weeks. Thus, it is likely that the outbreak has been contained for now. There have been 132 cases with 38 deaths, and it is likely that most deaths attributable to the infection have already occurred. We can now safely assume a relatively reliable maximum mortality rate of about 30% for the cases that were diagnosed. Because we know that mild and asymptomatic disease do occur, the true mortality rate is undoubtedly lower.

New Vaccine Drives Africa Meningitis Cases to Lowest in Decade {#s4}
==============================================================

6 June 2013 (Reuters Health \[Kate Kelland\]) The World Health Organization (WHO) reported that case numbers in Africa\'s meningitis season this year were the lowest in a decade, thanks to a cheap new vaccine designed to treat a form of the disease common in the so-called meningitis belt. The vaccine, called MenAfriVac, was developed with funding from the Bill & Melinda Gates Foundation specifically for use against meningococcal meningitis type A, a type of meningitis that causes regular epidemics in Africa.

Detailing data for 1 January through 12 May, the United Nations health agency said that just under 9250 meningitis cases, including 857 deaths, were reported in 18 of the 19 African countries under enhanced surveillance for meningitis.

Epidemics of meningitis A occur regularly in Africa\'s meningitis belt, a band of 26 countries stretching from Senegal to Ethiopia, and are particularly devastating to children and young adults. According to the non-profit Meningitis Vaccine Project (MVP), which helped develop the MenAfriVac vaccine, the seasonal outbreak of meningococcal meningitis across sub-Saharan Africa in 2009 infected ≥88 000 persons and killed \>5000.

The WHO said the falling numbers this year were due to the introduction of the newly developed vaccine. MenAfriVac costs just 50 US cents a dose and has been progressively introduced in Africa since 2010, starting in Burkina Faso, Mali, and Niger.

"The introduction of this first meningococcal vaccine available for preventive purposes in Africa has enabled the immunization of over 100 million people from 10 countries in the meningitis belt in the past three years," the WHO said. "The reduced case load and epidemic activity observed this year adds to the evidence on the impact ... of this vaccine."
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***Editorial comment.*** Although we do not see epidemics caused by meningococcal meningitis type A here, they have been devastating in sub-Saharan Africa. This vaccine resulted in about an 89% decrease in disease and an 83% decrease in deaths. The vaccine is probably even more effective, because these numbers assume 100% vaccination of the population.
